Mirae Asset Global ETFs Holdings’s Protalix BioTherapeutics PLX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$79.4K	Buy	34,097 +35	+0.1%	+$74	﹤0.01%	2918
2026 Q1	$73.9K	Buy	34,062 +816	+2%	+$2.02K	﹤0.01%	2801
2025 Q4	$59.8K	Buy	33,246 +993	+3%	+$2.03K	﹤0.01%	2886
2025 Q3	$71.6K	Sell	32,253 -5,822	-15%	-$9.48K	﹤0.01%	2817
2025 Q2	$56.4K	Buy	+38,075	New	+$77.9K	﹤0.01%	2854
2024 Q3	–	Sell	-34,167	Closed	-$40K	–	3161
2024 Q2	$40K	Buy	+34,167	New	+$40.4K	﹤0.01%	2834

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's PLX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Protalix BioTherapeutics (PLX) stake by 0.1% in Q2 2026, buying an estimated $74 and bringing the position to 34,097 shares worth $79.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2918.

Mirae Asset Global ETFs Holdings first reported a position in PLX in Q2 2024 and has held it in 6 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Mirae Asset Global ETFs Holdings held 34,097 shares of Protalix BioTherapeutics worth $79.4K as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 35 Protalix BioTherapeutics shares in Q2 2026, an estimated $74.
Protalix BioTherapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2918 holding.
Mirae Asset Global ETFs Holdings first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 6 quarters since.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.